MX2019001958A - Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. - Google Patents

Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.

Info

Publication number
MX2019001958A
MX2019001958A MX2019001958A MX2019001958A MX2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A MX 2019001958 A MX2019001958 A MX 2019001958A
Authority
MX
Mexico
Prior art keywords
methods
disease
treating crohn
antibody
nkg2d antibody
Prior art date
Application number
MX2019001958A
Other languages
English (en)
Spanish (es)
Inventor
Curran Mark
Brodmerkel Carrie
Greenbaum Linda
TELESCO Shannon
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2019001958A publication Critical patent/MX2019001958A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019001958A 2016-08-19 2017-08-17 Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. MX2019001958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377358P 2016-08-19 2016-08-19
PCT/US2017/047357 WO2018035330A1 (en) 2016-08-19 2017-08-17 Methods of treating crohn's disease with an anti-nkg2d antibody

Publications (1)

Publication Number Publication Date
MX2019001958A true MX2019001958A (es) 2019-06-13

Family

ID=61197073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001958A MX2019001958A (es) 2016-08-19 2017-08-17 Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.

Country Status (9)

Country Link
US (1) US20190292265A1 (enExample)
EP (1) EP3500293A4 (enExample)
JP (1) JP2019528285A (enExample)
KR (1) KR20190038919A (enExample)
AU (1) AU2017312049A1 (enExample)
CA (1) CA3034324A1 (enExample)
MA (1) MA45997A (enExample)
MX (1) MX2019001958A (enExample)
WO (1) WO2018035330A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP2021525243A (ja) 2018-05-21 2021-09-24 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Nk細胞による標的細胞の殺傷を増進するための組成物および方法
WO2020010139A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
WO2021057988A1 (zh) * 2019-09-27 2021-04-01 廖睿 检测粪钙卫蛋白含量的试剂在制备输卵管病变筛查试剂盒中的用途
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082110A2 (en) * 2004-02-26 2005-09-09 Illumina Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
JP5882208B2 (ja) * 2009-07-30 2016-03-09 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドによるクローン病の治療
WO2011082382A2 (en) * 2009-12-31 2011-07-07 The Trustees Of Columbia University In The City Of New York Methods for detecting and regulating alopecia areata and gene cohorts thereof
MX389057B (es) * 2015-01-26 2025-03-20 Allogene Therapeutics Inc Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.

Also Published As

Publication number Publication date
JP2019528285A (ja) 2019-10-10
EP3500293A4 (en) 2020-08-19
US20190292265A1 (en) 2019-09-26
CA3034324A1 (en) 2018-02-22
AU2017312049A1 (en) 2019-02-21
WO2018035330A1 (en) 2018-02-22
MA45997A (fr) 2019-06-26
KR20190038919A (ko) 2019-04-09
EP3500293A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
ZA201708265B (en) Tigit-binding agents and uses thereof
ZA202005388B (en) Methods of treating ulcerative colitis
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
EA201791093A1 (ru) Антитела к cd47, способы и применение
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
PH12017500493A1 (en) Combination therapy
MX384424B (es) Agentes de unión al determinante de grupo 123 y usos de éstos.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2018005107A (es) Composiciones y metodos para la terapia relacionada con la microbiota fecal.
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
GEP20217317B (en) Combination therapy for the treatment of cancer
IL276896A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use